Sign In
Buy SVA
$6.47
+0 (+0%)
At Close: Feb 07, 2020
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
05:40am, Monday, 12'th Jul 2021
BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it had signed an adva
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced The Lancet Infectious Diseases p
Pandemic Accelerates China's Drive Into mRNA Treatments
11:23am, Friday, 18'th Jun 2021
Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese compan
Sinovac CEO Yin Discusses CoronaVac's Efficacy
06:36pm, Tuesday, 11'th May 2021
May.11 -- Sinovac Biotech Ltd.'s vaccine is wiping out Covid-19 among health workers in Indonesia, an encouraging sign for the dozens of developing countries reliant on the controversial Chinese shot,
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines
02:00am, Monday, 10'th May 2021
The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine
Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
06:51pm, Thursday, 22'nd Apr 2021
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 2
Sinovac Announced Buildup of Two Billion Annual Capacity of Its COVID-19 Vaccine
11:30pm, Thursday, 01'st Apr 2021
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the third production
Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine
07:30am, Monday, 08'th Feb 2021
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Med
Sinovac Announces Phase III Results of Its COVID-19 Vaccine
04:05pm, Friday, 05'th Feb 2021
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced phase III results. Sinovac
Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China
09:53am, Wednesday, 03'rd Feb 2021
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has officially fil
Week In Review: Suzhou's Adagene To Stage $125 Million IPO On NASDAQ
04:39pm, Sunday, 24'th Jan 2021
Week In Review: Suzhou's Adagene To Stage $125 Million IPO On NASDAQ
Sinovac shareholder settles compliance probe with SEC
07:52am, Wednesday, 23'rd Dec 2020
Chinese vaccine maker Sinovac Biotech Ltd's shareholder 1Globe Capital LLC said on Wednesday it had settled with the U.S. Securities and Exchange Commission an investigation into its regulatory disclo
BEIJING and BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- 1Globe Capital LLC (“1GlobeCap”), a principal and long-term shareholder of Sinovac Biotech (NASDAQ: SVA) (“Sinovac”), has reached agreemen
Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day
03:15pm, Sunday, 13'th Dec 2020
JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. Beijing's Sinovac Biotech reporte
Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine
07:30am, Wednesday, 09'th Dec 2020
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Med
